DUN T1
Orally Administered Drug for Type-1 Diabetes
StartupDUN T1 is a Meishar-based startup in the Health Tech & Life Sciences sector, established in 2017. Orally Administered Drug for Type-1 Diabetes. The company has raised a total of $45K across 1 funding round, currently at the Seed stage. DUN T1 was founded by Daniella Givon, Raanan Margalit, Nadav Shraibom. Key investors include Fundit. The company has 1-10 employees.
With $45K in total funding, DUN T1 is a Seed-stage company operating in Health Tech & Life Sciences. The company follows a B2B2C business model. Product stage: R&D. The company holds 1 patent.
- StageSeed
- ProductR&D
- ModelB2B2C
- Employees1-10
- HQMeishar
- DistrictCenter District
- Last Round$45K
- Fundit
Daniella GivonCEO & Head of R&D
Raanan MargalitHead of Pre-Clinical Studies
Nadav ShraibomHead of Strategy Affairs
What does DUN T1 do?
DUN T1 is an early-stage R&D company that develops an orally administered drug for type 1 diabetes. DUN T1's vision is to develop a proactive approach towards treatment and early diagnosis. DUN T1's novel natural ingredient is patented, safe, and effective.
How much funding has DUN T1 raised?
DUN T1 has raised $45K in total funding across 1 rounds. The company is currently at the Seed stage. Key investors include Fundit.
Who founded DUN T1?
DUN T1 was founded in 2017 by Daniella Givon (CEO & Head of R&D), Raanan Margalit (Head of Pre-Clinical Studies), Nadav Shraibom (Head of Strategy Affairs).
What sector is DUN T1 in?
DUN T1 operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development. Target customers: Commerce & Retail, Distribution Channels, Distributor, Healthcare & Life Sciences, Life Sciences, Pharmaceuticals, Healthcare, Patients.
Where is DUN T1 located?
DUN T1 is based in HaDuhifat Street 34, Meishar, Israel, Center District.